Market news, stock analysis and investing ideas

SELLAS Phase 3 AML Win Lifts SLS 156%, Then a $150 Million Offering Follows

SELLAS said its AML vaccine met the main goal of a Phase 3 trial. Shares closed up 156.36% from Monday after a pre-market high of $34.19, then traded lower after hours once the company filed for a $150 million stock offering.

Sellas

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) said on Nov. 17 that its Phase 3 REGAL trial of galinpepimut-S (GPS), a vaccine for acute myeloid leukemia (AML), met its primary goal of improving overall survival, according to an 8-K filed at 7:14 a.m. ET, before the open. At 4:14 p.m. ET, in after-hours trading, it filed a preliminary prospectus supplement for a $150 million common stock offering.

A tripling pre-market, a 20% fade, then new share supply

The REGAL result sent SLS from Monday's $7.47 close to a pre-market high of $34.19. The stock fell 20.21% during the regular session from its pre-market close and still finished up 156.36% on the day. The offering filing arrived after the close, and shares traded lower in after-hours trading.

Shares more than tripled pre-market, then fell back

Nasdaq halted SLS at 6:55 a.m. ET with news pending, and trading resumed at 7:30 a.m. The stock had already gained 6.96% in Monday's after-hours session (trading after the 4 p.m. close), reaching $7.99, before the trial news.

In pre-market trading (the session before the 9:30 a.m. open), SLS was at $24.00 at 9:29 a.m., up 221.29% from Monday's close. About 25.71 million shares changed hands in that session.

Two volatility pauses hit in the regular session, from 9:35 a.m. to 9:45 a.m. and from 9:50 a.m. to 9:55 a.m. The stock ranged from $16.70 to $24.89 and closed at $19.15, up 156.36% from Monday's close. Volume was 88.23 million shares, against a 10-day average of about 6.5 million.

In after-hours trading, SLS was at $16.99 at 4:46 p.m., down 11.28% from the 4 p.m. close, on about 5.30 million shares. It is not clear whether the slide began before the 4:14 p.m. filing.

Before the news, SLS had fallen 28.79% over the sessions from Oct. 19 to Nov. 16. It closed below $8.50 in each of the last five sessions, ending at $7.47 on Monday.

What the trial data and the offering add to the picture

The company said GPS cut the risk of death by 41%, with a hazard ratio of 0.59 (a ratio below 1 means lower risk in the treated group) and a p-value of 0.035. Median overall survival was 24.0 months with GPS versus 14.7 months with the investigator's choice of best available treatment.

The offering covers up to $150 million of common stock, and underwriters have a 30-day option to buy more, according to the filing. The prospectus is preliminary and subject to completion, and it cites Monday's $7.47 close as the last reported price. The float (shares available to trade) was about 200.08 million shares.

What REGAL showed and what remains open

  • The analysis was run after the pre-specified 80 deaths, the company said.
  • The trial enrolled AML patients in second or later complete remission who were ineligible for, or unable to undergo, a stem cell transplant.
  • The company said GPS was generally well tolerated, with mostly mild to moderate side effects such as injection site reactions, and no new safety signals.
  • Secondary endpoints and other analyses are still being evaluated. The company said it will present them at a future major medical conference and submit them for peer-reviewed publication.

SELLAS also has a second AML program, SLS009. It said on Nov. 4 that it would present Phase 2 data for it at the ASH 2026 meeting.

Next steps for GPS and the offering

  • Pricing of the stock offering and any exercise of the underwriters' 30-day option.
  • A meeting with the FDA to discuss an accelerated filing strategy, with no date given.
  • A Biologics License Application (BLA), the formal request for approval, which the company is preparing for the first half of 2027.
  • Detailed secondary-endpoint results at a medical conference, with no date given.
  • The ASH 2026 presentation of SLS009 data.

Bottom line

REGAL gave SELLAS a positive Phase 3 result and a stated path toward an FDA filing in the first half of 2027. The stock ended the regular session at $19.15, well above Monday's $7.47 but 20.21% below its pre-market close.

The company's $150 million offering would add shares, and the final terms are not yet in the preliminary filing. After-hours trading at $16.99 was still in progress at 4:46 p.m. ET.


This article was processed by WSN Finance AI Analysis and prepared by WSN Editors based on financial analysis.

This article is for informational purposes only and is not investment advice.

Read the original report